CD Biosynsis offers accelerated Mammalian Cells Strain Development and Screening Services, utilizing advanced genome editing and high-throughput platforms to optimize production cell lines, primarily CHO (Chinese Hamster Ovary) cells and HEK293 cells. Mammalian cells are the industry standard host for producing complex, high-value biotherapeutics, including monoclonal antibodies (mAbs), fusion proteins, and biosimilars, which require accurate human-like post-translational modifications (PTMs). Our services leverage high-precision genome editing (CRISPR-Cas9, Base Editing) with automated High-Throughput Screening (HTS) technologies to rapidly generate, evaluate, and optimize thousands of genetic variants. We specialize in engineering mammalian cell lines for enhanced specific productivity ($\text{Q}_{\text{p}}$), improved product quality (e.g., tailored glycoprofile), prolonged viability under fed-batch conditions, and robustness against industrial stressors, providing a fast track to the commercial Master Cell Bank (MCB).
Get a QuoteStrain development in mammalian cells is centered on enhancing two major attributes: high volumetric productivity and consistent Critical Quality Attributes (CQAs). Our integrated platform significantly accelerates the optimization cycle by utilizing CRISPR-mediated metabolic engineering (e.g., knockout of pro-apoptotic genes or lactate-producing enzymes) and PTM pathway tuning (e.g., $\alpha(1,6)$-Fucosyltransferase editing). We couple this with automated liquid handling, miniaturized culture systems, and multi-parameter HTS assays to quickly evaluate monoclonal cell lines for high $\text{Q}_{\text{p}}$ and desired glycoprofiles. This rapid, data-driven approach dramatically reduces the timeline for establishing a verified, high-performance Master Cell Bank (MCB).
CRISPR-Cas9 Editing (KI/KO)
Used for stable integration of therapeutic genes into genomic safe harbor loci (KI) and multi-allelic deletion of pro-apoptotic genes or proteases (KO) in CHO cells.
Base Editing (BE) / CRISPRi
For high-precision, single-nucleotide substitutions (BE) to tune promoter strength, or tunable repression (CRISPRi) to manage metabolic flux (e.g., lactate reduction).
Optimized Delivery (RNP/Lentivirus)
Preference for RNP delivery for transient, clean edits, and Lentivirus for stable integration in hard-to-transfect cell lines, maximizing safety and editing speed.
Automated Single-Cell Cloning
Use of automated systems (e.g., ClonePix, FACS) and limiting dilution to isolate and verify single, viable cells, ensuring the generation of true monoclonal cell lines.
Productivity Assays (ELISA/Titer)
Implementation of rapid, high-throughput assays to quantify specific productivity ($\text{Q}_{\text{p}}$) and growth metrics in miniaturized 96/384-well plates.
CQA & Metabolite HTS
Miniaturized analytical assays for early screening of Critical Quality Attributes (CQAs) like glycoprofile and charge variants, and detection of toxic metabolites (lactate/ammonia).
Glycosylation Engineering
Systematic editing (KO of FUT8 to create low-fucose mAbs, KI of specific glycosyltransferases) to optimize therapeutic N-glycan profiles.
Metabolic Pathway Control
Engineering to reduce the Warburg effect (e.g., LDHA repression) and enhance TCA cycle flux, leading to reduced lactate and extended culture lifespan.
Anti-Apoptosis & Fitness
Targeted deletion or repression of pro-apoptotic genes (e.g., Bax, Bak) to enhance cell survival under industrial stress and boost final volumetric titer.
Integrated cycle for rapid, iterative strain optimization using advanced tools.
1. Rational Design & Library Generation
2. Genomic Modification & Selection
3. High-Throughput Screening & Cloning
4. Clonal Verification & MCB Delivery
Computational modeling and functional genomics identify optimal genetic targets (KO, KI, tuning) for productivity and quality.
Design gRNAs and expression cassettes for targeted editing (e.g., Base Editing library for promoter tuning).
Select stable genomic safe harbor loci for therapeutic gene integration.
Deliver the editing system (CRISPR/BE/CRISPRi) and donor templates into the mammalian host (Build).
Execute multiplex gene editing and select for stable integration clones using metabolic or antibiotic markers.
Genotype the bulk population to confirm successful editing and integration.
Analyze HTS data to correlate genotype with desired phenotype ($\text{Q}_{\text{p}}$, glycoprofile) and select the lead clone (Learn).
Genomic verification (sequencing) and stability testing of the final clone over multiple passages.
Delivery of the verified Master Cell Bank (MCB) and comprehensive documentation.
Productivity & Viability
Targeted metabolic and anti-apoptotic engineering maximizes cell longevity and redirects carbon flux away from toxic byproducts (lactate/ammonia), boosting final titer.
Precision Glycan Control
CRISPR-based control over fucosylation (FUT8 KO) and galactosylation pathways ensures the production of highly specific, clinically relevant therapeutic antibodies and proteins.
Stable Genomic Integration
Focus on CRISPR/HDR knock-in into verified genomic safe harbor loci ensures robust, consistent, and stable expression, critical for regulatory acceptance.
Automated HTS & Analytics
Integration of automation, miniaturization, and rapid CQA screening significantly shortens the timeline required to isolate the optimal, high-performing monoclonal producer clone.
1. What is the role of HTS in mammalian cell line development?
HTS rapidly screens thousands of single-cell clones post-editing/transfection. It identifies the rare, optimal clones with the highest specific productivity ($\text{Q}_{\text{p}}$), optimal CQAs, and favorable growth characteristics in miniaturized culture systems.
2. How is the glycoprofile of an mAb optimized in CHO cells?
The glycoprofile is optimized primarily by knocking out $\alpha(1,6)$-Fucosyltransferase (FUT8) to increase ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) or by knocking in specific glycosyltransferases to enhance sialylation or core fucosylation.
3. How does gene editing reduce lactate production (Warburg effect)?
We use tools like CRISPRi or Base Editing to repress or subtly reduce the expression/activity of lactate dehydrogenase (LDHA) and pyruvate dehydrogenase kinase (PDK), redirecting glucose flux toward the efficient TCA cycle.
4. How is the genetic stability of the final clone ensured?
Stability is ensured by selecting clones where the therapeutic gene and host modifications are integrated into verified genomic safe harbor loci (via CRISPR/HDR) and verified by long-term passaging stability tests.
5. What HTS technology is used for single-cell cloning?
We use automated systems like ClonePix and Fluorescence-Activated Cell Sorting (FACS) to select single cells based on viability and high productivity (via secreted product detection or reporter genes).
6. Why is anti-apoptosis engineering necessary for CHO cells?
Anti-apoptosis engineering prevents programmed cell death triggered by nutrient deprivation, high osmolality, and byproduct accumulation (common in fed-batch), extending the viable, high-production phase of the culture.
7. What input is required to start a strain development project?
We require the specific mammalian host cell line (e.g., CHO-K1), the therapeutic gene sequence (mAb, fusion protein, etc.), and the primary optimization goals (e.g., titer, fucose level, viability).
8. What is included in the Master Cell Bank (MCB) delivery?
The MCB consists of a cryopreserved batch of the final verified clonal cell line, accompanied by a comprehensive report detailing all genomic modifications, stability data, and bioreactor performance metrics.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.